



ASX ANNOUNCEMENT

MINIMUM HOLDING BUY-BACK CLOSED

SYDNEY, Tuesday, 21 May 2019: Cellmid Limited (ASX: CDY) advises that the Closing Date for submission of Share Retention Forms in relation to the Minimum Holding Share Buy-Back has now passed (ASX announcement, 19 March 2019).

Pursuant to the Buy-Back offer 499,117 fully paid ordinary shares will be bought back by the Company at 23 cents per share for a total consideration of \$114,796.91. The shares being bought back are held by 558 shareholders, representing 28.9% of the Company's total shareholders.

The Buy-Back was conducted to assist those Shareholders with an unmarketable parcel to sell and realise their shares without incurring brokerage and other expenses as well as substantially reducing the Company's administrative costs associated with maintaining a larger share register.

The proceeds will be distributed to Shareholders that participated in the Buy-Back shortly and the shares will be cancelled once transferred to the Company. Any Shareholders with a query in relation to the receipt of their proceeds should contact the Company's Share Registry on 1300 288 664 or hello@automic.com.au.

END

Company Maria Halasz, CEO Cellmid T +612 9221 6830 info@cellmid.com.au	Investor Relations & Media Rebecca Wilson WE Buchan T + 61 417 382 391 wilson@we-buchan.com
--	--

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid also has two wholly owned subsidiaries, Lyramid and Kinera, which develop innovative novel therapies and diagnostic tests for fibrotic diseases, cancer and ischemic diseases of the heart. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.